Medifast (NYSE:MED) Stock: Insider Daniel Chard Sells 9,545 Shares

Key Points

• Director Daniel Chard sold 9,545 Medifast shares at an average price of $11.98, totaling $114,349.10. The Rule 10b5-1 transaction reduced his direct ownership by 6.38% to 140,153 shares.
• Medifast shares recently traded near $11.53, within a 52-week range of $9.22 to $14.15. The company reported quarterly revenue of $76.38 million and adjusted its outlook to remain unprofitable in fiscal 2026.
• Analyst sentiment remains cautious: two analysts rate the stock Hold and one rates it Sell, producing a consensus “Reduce” rating and an average price target of $12.00. Institutional investors own approximately 95.51% of the company.

Medifast Inc (NYSE:MED - Get Free Report) Director Daniel Chard sold 9,545 shares of the stock in a transaction that occurred on Monday, September 28th. The shares were sold at an average price of $11.98, for a total transaction of $114,349.10. Following the sale, the director directly owned 140,153 shares of the company's stock, valued at approximately $1,679,032.94. This trade represents a 6.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Medifast Price Performance

Shares of MED stock traded down $0.09 during mid-day trading on Wednesday, hitting $11.53. The company had a trading volume of 138,133 shares, compared to its average volume of 113,400. Medifast Inc has a 52-week low of $9.22 and a 52-week high of $14.15. The stock's 50 day moving average price is $11.67 and its 200-day moving average price is $11.34. The company has a market capitalization of $128.85 million, a P/E ratio of -4.95 and a beta of 0.71.

Medifast (NYSE:MED - Get Free Report) last issued its earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.37. Medifast had a negative net margin of 8.08% and a negative return on equity of 6.69%. The firm had revenue of $76.38 million during the quarter, compared to analyst estimates of $72.70 million. Medifast has set its FY 2026 guidance at -1.750--0.250 EPS and its Q3 2026 guidance at -0.650--0.150 EPS. On average, equities research analysts expect that Medifast Inc will post -1.04 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on MED. Weiss Ratings raised Medifast from a "sell (e+)" rating to a "sell (d)" rating in a report on Monday, August 17th. Zacks Research lowered shares of Medifast from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 11th. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Reduce" and an average target price of $12.00.

Institutional Trading of Medifast

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. State of Wyoming lifted its position in shares of Medifast by 19.8% during the first quarter. State of Wyoming now owns 6,646 shares of the specialty retailer's stock worth $68,000 after purchasing an additional 1,097 shares during the last quarter. Ancora Advisors LLC purchased a new stake in Medifast in the 2nd quarter valued at about $75,000. Quantinno Capital Management LP grew its stake in Medifast by 15.1% in the 1st quarter. Quantinno Capital Management LP now owns 56,153 shares of the specialty retailer's stock worth $572,000 after acquiring an additional 7,346 shares in the last quarter. Engineers Gate Manager LP grew its stake in Medifast by 25.9% in the 2nd quarter. Engineers Gate Manager LP now owns 49,829 shares of the specialty retailer's stock worth $529,000 after acquiring an additional 10,249 shares in the last quarter. Finally, Ieq Capital LLC purchased a new position in shares of Medifast during the second quarter worth approximately $114,000. Hedge funds and other institutional investors own 95.51% of the company's stock.

About Medifast

Medifast, Inc NYSE: MED is a health and wellness company that provides weight-management and healthy-lifestyle products and programs. Its principal brand is OPTAVIA, which offers structured plans designed to support weight loss, nutrition, and long-term habit development.

The company's product portfolio includes meal-replacement shakes, bars, snacks, entrees, beverages, supplements, and other packaged “Fuelings.” Medifast also supports customers through independent OPTAVIA Coaches, who provide guidance, accountability, and lifestyle support through the company's direct-selling model.

Founded in 1980, Medifast serves customers primarily in the United States through its e-commerce and direct-to-consumer channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.